Sixty-four eyes were prospectively investigated. Group 1 (22 central retinal vein occlusion (CRVO) and 16 branch retinal vein occlusion (BRVO)) was treated with Ozurdex alone, and group 2 (14 CRVO and ...

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE: AGN) announced today that the U.S. Food and Drug Administration (FDA) has approved OZURDEX® (dexamethasone intravitreal implant) 0.7 mg, a ...

Please provide your email address to receive an email when new articles are posted on . Intravitreal steroids have been widely used in the treatment of various ocular pathologies including macular ...

A sustained-release dexamethasone device implanted during pars plana vitrectomy may be effective in pre-emptively reducing macular edema in patients with various underlying ocular diseases at risk for ...

Ozurdex is a biocompatible implant licensed for the treatment of cystoid macular oedema (CMO) after retinal vein occlusions. We report a case of anterior vitreous displacement of Ozurdex, discussing ...

Purpose To report outcome of eyes with recalcitrant and naive eyes with diabetic macular edema (DME) treated with intravitreal dexamethasone implants (Ozurdex) injection. Methods Retrospective ...

OZURDEX (dexamethasone) intravitreal implant by Allergan The FDA has approved Ozurdex (dexamethasone intravitreal implant, from Allergan) for the treatment of non-infectious ocular inflammation, or ...

Treatment becomes an option for treating visual impairment caused by diabetic macular oedema, regardless of lens status Treatment becomes an option for treating visual impairment caused by diabetic ...

OZURDEX (dexamethasone) intravitreal implant by Allergan Allergan's Ozurdex (dexamethasone intravitreal implant) has been approved by the FDA for the treatment of macular edema following branch ...

Biodegradable implant delivers extended-release corticosteroid dexamethasone via intravitreal injection. FDA cleared Allergan’s Ozurdex® 0.7 mg for noninfectious ocular inflammation, or uveitis, ...

NEW YORK (CBS 2) -- It's an eye condition you've probably never heard of, yet it's behind one of every six cases of blindness in the country. CBS 2HD's Dr. Max Gomez reports on a new way to stop ...

A total of 102 eyes of 85 subjects who received Ozurdex for DME were evaluated. Twenty-three eyes, which had <1 year follow-up, were excluded. Finally, 79 eyes of 62 subjects were included in this ...